Introduction. When performing therapeutic and diagnostic measures aimed at screening for prostate cancer, oncologists do not always take into account the urological history of patients and resort to antibiotic prophylaxis without taking into account the characteristics of microbial flora and antibiotic resistance in this group of patients.

Purpose. To study the effectiveness of the combined antimicrobial drug Combiflox manufactured by Micro labs (India) in the prevention of infectious complications after transrectal multifocal prostate biopsy.

Materials and methods. The study included 60 men aged 40 to 75 years (mean age 56.4 years) who underwent transrectal multifocal prostate biopsy under ultrasound guidance. With the aim of prevention of infectious complications assigned to combined anti-microbial drug "Combiflex", which contains 500 mg of Ornidazole and 200 mg of ofloxacin, and 1 tablet 2 times a day for 2 days before the manipulation, time manipulation, and for 2 days after the conference. The active follow-up period after the patient was included in the study was 18 days.

Results. In 59 cases, the use of combined antimicrobial drug Combiflex with transrectal multifocal prostate biopsy infectious complications were not recorded. The efficiency was 98.3%.

Summary. The use of the combined antimicrobial drug Combiflox in transrectal multifocal prostate biopsy for the prevention of infectious complicationsis highly effective and has a minimum number of undesirable side effects, as well as microbiologically justified taking into account potential pathogens in transrectal access.

Authors declare lack of the possible conflicts of interests.